Ista Pharmaceuticals Inc trades in the stock market as ticker ISTA. Business Summary & Profile For Ista Pharmaceuticals Inc.

Ista Pharmaceuticals Inc

ISTA Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets remedies for diseases and conditions of the eye in the United States. It offers products to treat allergy and serious disease of the eye; and therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. The company provides BROMDAY for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extractions; BEPREVE for ocular itching associated with allergic conjunctivitis; ISTALOL for the treatment of glaucoma; and VITRASE for use as a spreading agent. Its products under development include T-Pred for steroid responsive inflammation and allergic conjunctivitis; Strong steroid for ocular inflammation; REMURA for the treatment of dry eye syndrome; and BROMDAY (lower concentration) for postoperative inflammation and reduction of ocular pain. The company’s products under development also comprise Bepotastine nasal and Bepotastine nasal combination for allergic rhinitis. In addition, it is developing iganidipine to enhance ocular nerve blood flow; prostaglandin, a formulation of latanoprost, for the treatment of glaucoma; and ecabet sodium for dry eyes. ISTA Pharmaceuticals, Inc. sells its products to drug wholesalers, retailers, and distributors, such as chain of drug stores, hospitals, clinics, and government agencies, as well as health maintenance organizations and other institutions. The company was formerly known as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in March 2000. ISTA Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Irvine, California.
326 Employees
Last Reported Date: 02/25/11
Founded in 1992
LAST $8.30 USD
CHANGE TODAY -0.06 -0.72%
As of 8:09 PM 02/17/12 All times are local (Market data is delayed by at least 15 minutes).


04/6/11 - $11.39
10/4/11 - $2.88
ISTA Does Not Pay Dividends
K = Thousands  M = Millions  B = Billions

related news

No related news articles were found.


ISTA Pharmaceuticals To Review Strategic Options

The Board of Directors of ISTA Pharmaceuticals, Inc. today repeated its intention to maximize shareholder value and said it will continue its previously announced review of all strategic options available to ISTA. ISTA previously announced review of its strategic options on December 16, 2011 and is currently in dialogue with a number of parties that have expressed an interest in pursuing a strategic transaction and remains committed to maximizing shareholder value.

ISTA Pharmaceuticals Inc. Initiates Phase 2 Clinical Study of BEPOSONE for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis

ISTA Pharmaceuticals Inc. announced it has initiated a Phase 2 clinical study of its BEPOSONE(TM) nasal spray combining bepotastine besilate with a steroid for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group environmental study will evaluate the safety and efficacy of the combination nasal spray, dosed twice daily, in patients presenting with allergic rhinitis caused by one of the most potent seasonal allergy triggers, Mountain Cedar pollen. ISTA expects to enroll approximately 600 patients in Texas who will be treated with either the bepotastine besilate-steroid combination nasal spray, nasal spray containing only one of the active agents, or placebo nasal spray for two weeks. Patients will grade both individual nasal and ocular symptoms on a daily basis during the treatment period.

ISTA Pharmaceuticals Inc. Provides Earnings Guidance for the Years 2011 and 2012

ISTA Pharmaceuticals Inc. provided earnings guidance for the years 2011 and 2012. For the year 2011, the company expects unaudited net revenues t net revenues above $160 million and expects to be profitable in 2011 for the second consecutive year on an adjusted cash net income basis. For the year 2012, the company expects net revenues will be approximately $180 million to $195 million, adjusted cash net income will be $15 million to $19 million, or fully diluted earnings per share of $0.28 to $0.36, assuming 53 million fully diluted shares, adjusted EBITDA (or adjusted cash net earnings before interest, taxes, depreciation and amortization) will be $25 million to $29 million.

ISTA Competitors

Company Last Change
Cornerstone Therapeutics Inc $6.23 USD 0.00
Hi-Tech Pharmacal Co Inc $39.03 USD -0.70
Lannett Co Inc $4.67 USD -0.06
OraSure Technologies Inc $10.46 USD -0.30
Sucampo Pharmaceuticals Inc $6.88 USD +0.05
Market data is delayed at least 15 minutes.

Industry Analysis

Valuation ISTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x



ISTA transactions

December 16, 2011
No related news found for this Ista Pharmaceuticals Inc.

Write Comment Create Account

Quotes are delayed for NASDAQ, NYSE, OTC, OTCBB (Penny Stocks) and NYSE Amex when available. Quotes and other information supplied by independent providers and feeds. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Localnewsnor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing Localnews, you agree not to redistribute the information found therein.

Privacy Policy - WE KEEP YOUR PERSONAL DATA PRIVATE AND CONFIDENTIAL - Localnews is committed to protecting the privacy of all our visitors and subscribers. Your right to privacy is very important to us. When you choose to provide us with information about yourself, we recognize that you trust us to act in a responsible manner. SHARING OF INFORMATION - Localnews does not sell, rent, lease or share any user information that it has collected over this website.

@2012 - Contact Us / Privacy Policy